Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» November 2010
November 2010
Options Action: Johnson & Johnson
Options Action: Johnson & Johnson
CNBC
JNJ
options
Ariad Gets Good News on Its Endometrial Cancer Drug
Ariad Gets Good News on Its Endometrial Cancer Drug
Seeking Alpha
endometrial cancer
Ariad Pharmaceuticals
Merck
mTOR inhibitors
ridaforolimus
J&J Recalls Children's Benadryl, Motrin Over Manufacturing `Deficiencies'
J&J Recalls Children's Benadryl, Motrin Over Manufacturing `Deficiencies'
Bloomberg
recalls
JNJ
Let's Call It a Partial Victory (Merck)
Let's Call It a Partial Victory (Merck)
Motley Fool
Merck
Vytorin
kidney disease
Abbott drug meets goals in kidney disease study
Abbott drug meets goals in kidney disease study
Yahoo/AP
kidney cancer
Abbott Laboratories
atrasentan
Pfizer's Mixed Bag
Pfizer's Mixed Bag
Motley Fool
Pfizer
Apixaban
JNJ
Boehringer Ingelheim
Bristol-Myers Squibb
Axitinib
Celldex advances brain tumor vaccine
Celldex advances brain tumor vaccine
Bizjournals.com
vaccines
Celldex
brain tumors
brain cancer
Genzyme ($GENZ) proffers milestone-based deal to potential suitors
Genzyme ($GENZ) proffers milestone-based deal to potential suitors
Fierce Biotech
Genzyme
milestone payments
Sanofi
M&A
Pfizer
Merck
JNJ
Merck, Vytorin & Questionable Oxford Researchers
Merck, Vytorin & Questionable Oxford Researchers
Pharmalot
Merck
Vytorin
Apricus, FDA agree on design for late-stage study of liver cancer drug PrevOnco; stock surges
Apricus, FDA agree on design for late-stage study of liver cancer drug PrevOnco; stock surges
Yahoo/AP
Apricus Biosciences
FDA
liver cancer
PrevOnco
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »